ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM

FRIDAY, April 4, 2025-- For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment...